Simple Hyperplasia (without atypia)
Complex Hyperplasia ( without atypia) Atypical hyperplasia Tubular or cystic glands with minimal non complex budding, branching or papillary infoldings.
Complex glands with frequent intraluminal epithelial projections and intraglandular bridging simulating cribriform structures.
May be simple (rare) or Complex ( Common) Glands -to-stroma ratio >3:1, Marked crowding (i.e., back to back glands) rare.
Glands -to-stroma ratio >>3:1, Marked crowding with back to back glands common.
Glands -to-stroma ratio >3:1 or >>3:1, Marked crowding with back to back glands common. Nuclear pseudo-stratification (nuclei resemble mid -to -late proliferative endometrium) Inconspicuous nucleoli, No pleomorphism.
Nuclear pseudo-stratification (nuclei resemble mid -to -late proliferative endometrium) Inconspicuous nucleoli, No pleomorphism.
Nuclear pseudo-stratification with loss of polarity. Prominent nucleoli, Variation in nuclear size and shape often rounded. designates four different types with varying malignant potential (Kurman, 1985) .Hyperplasias are classified as simple and complex depending on glandular complexity and crowding .Most important, hyperplasias are further designated as atypical if they demonstrate cytologic atypia.
Only atypical endometrial hyperplasias are clearly associated with the subsequent development of adenocarcinoma.
World Health Organization Classification of Endometrial Hyperplasia

Types
Progressing to Cancer(%)
Simple hyperplasia 1
Complex hyperplasia 3
Simple atypical hyperplasia 8
Complex atypical hyperplasia 29
CYSTIC GLANDULAR HYPERPLASIA:
Synchronize proliferation of glands and stroma produces endometrium that has normal gland to stromal ratio. Glands are tubular or cystically dilated with shallow budding.
ADENOMATOUS HYPERPLASIA:
Indicates glandular atypia and increased gland to stromal ratio. The malignant potential of adenomatous hyperplasia is high with severe structural and cytological atypia.
PROLIFERATIVE TYPE OF ENDOMETRIUM:
Proliferative typr of endometrium in AUB is an exageration of normal proliferative phase without significant increase in overall ratio of glands to stroma and is due to persistent eastrogen stimulation. 
II.
Methodology -Patients And Methods. After exclusion of adnexal (tubes and ovaries) and cervical lesions, uterus was examined to exclude any uterine lesion and to measure the endometrial thickness (ET) in a longitudinal view of the uterus. If ET was <4 mm expectant treatment was allowed but if bleeding recurred or persisted endometrial sampling was done. If ET was >4 mm endometrial sampling was done immediately without resorting to the expectant treatment.
Method Of Collection Of Data
Patients with isolated endometrial causes of postmenopausal bleeding were included 29 in the study. Endometrial sample was obtained by dilatation and curettage and examined histopathologically. Chi Square (χ2) test was used to asses risk factor analysis and percentage comparison for histopathological evaluation. The slides were reviewed and classified using current pathological criteria. The endometrial specimens were divided into the following histological categories: atrophic; proliferative; secretory; endometrial polyp; simple or cystic hyperplasia; atypical hyperplasia;carcinoma and others. The present study was approved by our institutional ethics board.
Procedure
Endometrial tissue was obtained by performing Dilatation & curettage under local anaesthesia. The endometrial tissue was fixed in 10% formalin for 12-24 hours and the entire tissue was taken for routine processing. 5μ thickness sections taken from paraffin blocks were stained with Haematoxylin and Eosin (H&E) and studied under light microscopy.
Sample size : 100 cases Inclusion Criteria: Endometrial biopsy taken by dilatation and curettage from a Post menopausal bleeding women.  Women not on any hormonal replacement therapy. Exclusion Criteria:  Expected cyclical bleeding that occurs in women taking sequential hormone replacement therapy.
III. Observation And Results
The following few pages will give a descriptive analysis of age distribution, parity distribution and menopause duration, medical co-morbidities distribution, type of endometrium in patients with PMB.The total numbers of patients studied were 100 from JANUARY 2014 to AUGUST 2015. In the present study maximum number of cases (36%) were in the age group of 56 -60 years and minimum number of cases (1%) were in the age group of 41-45 years. In the present study age range was 41-68 years and Mean age was 55.84 years. Postmenopausal bleeding was more common within 6-10yrs after reaching menopause. Maximum number of patients (45%) had duration of menopause between 6-10 years, indicating inverse relationship between duration of menopause and frequency of postmenopausal bleeding. In the present study 43% patients are associated with medical comorbidities (p<0.05). They are the independent risk factors associated with postmenopausal bleeding. In the present study histopathological findings are Atrophic endometrium (AE) 31%, Simple hyperplasia (SH) without atypia 27%, Simple hyperplasia (SH) with atypia 4%, Proliferative endometrium (PE)21%, Secretory endometrium (SE) 5%,Endometrial polyp (EP)4%, Endometrial carcinoma(EC)6%, Endometritis1% and Not Representative(NR)1%. It was observed that atrophic endometrium was the most common histological diagnosis i.e. in 31cases (31%) followed by different types of endometrial hyperplasia in 31(31%). Proliferative endometrium was observed in 21% of cases and one case (1%) of endometritis was seen. In our study of endometrial curettage of 100 cases who presented with complaints of postmenopausal bleeding, benign conditions were seen in (90%) cases which included atrophic endometrium, proliferative endometrium, secretory endometrium, benign endometrial polyp, endometritis and simple hyperplasia without atypia. Premalignant conditions such as hyperplasia with atypia seen in 4 (4%).
The malignant endometrial adenocarcinoma in 6 cases (6%). In the present study simple hyperplasia without atypia was common(8%) in the age group 46-50 years, proliferative endometrium was common (9%) in the age group (51-55) years, and atrophic endometrium was common in the age group more than 56 years.Endometrial carcinoma was common in age group more than 56 years. In the present study, benign lesions were seen in 40 cases with duration of menopause 1-5 years,43 cases with duration of menopause 6-10 years and in 11 cases with duration of menopause more than 10 years. Whereas malignant cases were seen with duration of menopause more than 6 years.2malignant cases were seen with duration of menopause 6-10 years and 4 with duration of menopause more than 10 years.
Tab
Tab No.9
Comparison of parity with endometrial carcinoma. 
IV. Discussion
The present prospective study includes 100 patients presented with post menopausal bleeding to gynaecology OP department. The famous dictum that "Postmenopausal bleeding must be considered as indicative of malignant disease until proven otherwise," still holds true in our circumstances 23 . The general consensus regarding management of PMB is that all patients must be excluded of cancer by biopsy. In the present study maximum number of cases (36%) were in the age group of 56 -60 years and minimum number of cases (1%) were in the age group of 41-45 years. While in the study of kothapally et al maximum number of cases were between 50-60 yrs (56.6%) and minimum in the age group of 45 to 50 yrs Postmenopausal bleeding was more common within 6-10yrs after reaching menopause. Maximum number of patients (45%) had duration of menopause between 6-10 years, similar to Opmeer B et al In 4 of 6 patients with endometrial carcinoma, malignancy was present when bleeding started >10 years after menopause. The incidence of malignancy increased with increase in period between menopause and onset of PMB. Number of benign cases were prominent in the 1-10 years of onset of menopause. Sonali rati et all (N = 174) 48.2% patients had associated medical disorders which is statistically significant , present study has 43% patients associated with medical comorbidity (p<0.05). They are the independent risk factors associated with postmenopausal bleeding. In Sonali rati et all study, 42.42% obese patients, 23% diabetic patients, 20% hypertensive patients and 40% nulliparous women had endometrial carcinoma which was statistically significant (p < 0.05).
In the Present study 33.3% of patients with endometrial carcinoma had medical comorbidity, 16.6% of patients with endometrial carcinoma had obesity.
It was observed that atrophic endometrium was the most common histological diagnosis i.e. in 31cases (31%) followed by different types of endometrial hyperplasia in 31(31%). The incidence of atrophy was found to be 49.9% by Gredmark T et al , 52.1 % by Lee WH et al 31 , 64.4% by Dangal G et al 32 and 53% by Kaur M et al 33 . They all reported endometrial atrophy as the commonest finding in patients with postmenopausal bleeding which is consistent with the present study. Philip H et al 35 found atrophic endometrium (13.3%) as the 36 postulated sclerotic degeneration of endometrial vessels as a cause of bleeding in atrophic endometrial. Hourihan et al stated anatomical vascular variations or local abnormal haemostatic mechanisms in the uterus as a cause of bleeding from atrophic endometrium. Simple endometrial hyperplasias without atypia were observed in 27% and it was the second most common finding next to atrophic endometrium. In other studies it ranged from 13.46% to 26.6%.Endometrial hyperplasia is a pathological condition of the endometrium which carries both clinical and pathological significance. It is one of the most important predisposing factors for the development of endometrial carcinoma. This risk is especially seen in atypical endometrial hyperplasia which carries the risk of associated endometrial carcinoma more than endometrial hyperplasia without atypia. In our study, atypical hyperplasia was observed in 4%. It was found to range from 1.8 to 8% in other studies.
In the present study, proliferative endometrium was observed in 21% which is comparable to the study of Phillip H et al who found 20%. It was observed to range from 4.2% to 25.92% in other studies, which was also observed in previous studies done by Kothapally K et al6, Caspie et al. Endometrial adenocarcinoma which is the most important and threatened cause of postmenopausal bleeding, was found in 6% in the present study, while others have found it to range from 6% to 12%. Histologically there were 6 cases of endometrioid adenocarcinoma. In obesity, there is increased peripheral conversion of adrenal androgen to estrogen by aromatization in adipocyte. Diabetes mellitus is associated with increase in estrogen level, hyperinsulinemia or elevated level of insulin like growth factor I (IGF-I). In nulliparity, there is prolonged unopposed estrogen stimulation. Estrogen induces glandular proliferation leading to thickening of endometrium. In our study of endometrial curettage of 100 cases which presented with complaints of postmenopausal bleeding, benign conditions were seen in (90%) cases which included atrophic endometrium, proliferative endometrium, secretory endometrium, benign endometrial polyp, endometritis and simple hyperplasia without atypia. Premalignant conditions such as hyperplasia with atypia seen in 4 (4%). The malignant endometrial adenocarcinoma in 6 cases (6%).
Surgical-Pathologic Finding
In the present study pathology remained not representative in 1 % of cases, which is lower than reported incidence quoted by Lidor A et al 38 
VI. Summary
The present prospective study includes 100 patients presented with post menopausal bleeding to gynaecology OP department. The general consensus regarding management of PMB is that all patients must be excluded of cancer by oriented biopsy.
In the present study maximum number of cases (36%), were in the age group of 56 -60 years and minimum number of cases (1%) were in the age group of 41-45 years. Age range was 41-68 years and Mean age in the present study was 55.84 years. Postmenopausal bleeding was more common within 6-10yrs after reaching menopause. Maximum number of patients (45%) had duration of menopause between 6-10 years.
The incidence of malignancy increased with increase in period between menopause and onset of PMB. Number of benign cases were prominent in the 1-10 years of onset of menopause. In 4 of 6 patients with endometrial carcinoma, malignancy was present when bleeding started >10 years after menopause.
The risk of endometrial cancer in women with post menopausal bleeding rises with age, peak incidence was observed in the age group of 55-70yrs. The mean parity was 2.68. The majority of patients i.e. 88(88%) had a parity of 2 or more , 5 were nulliparous. Only one case out of five cases of nullipara presented with postmenopausal bleeding was diagnosed with endometrial carcinoma.
In the Present study 33.3% of patients with endometrial carcinoma had medical comorbidity, 16.6% of patients with endometrial carcinoma had obesity, which is statistically significant.
The histopathological findings are Atrophic (AE) 31,%Simple hyperplasia (SH) without atypia 27%, Simple hyperplasia (SH) with atypia 4%, Proliferative(PE)21%, Secretory(SE) 5%,Endometrial polyp (EP)4%, Endometrial carcinoma(EC)6%, Endometritis1% and Not Representative(NR)1%.
It was observed that atrophic endometrium was the most common histological diagnosis i.e. in 31cases (31%) followed by different types of endometrial hyperplasia in 31(31%).
In our study of endometrial curettage of 100 cases which presented with complaints of postmenopausal bleeding, benign conditions were seen in (90%) cases which included atrophic endometrium, proliferative endometrium, secretory endometrium, benign endometrial polyp, endometritis and simple hyperplasia without atypia. Premalignant conditions such as hyperplasia with atypia seen in 4 (4%). The malignant endometrial adenocarcinoma in 6 cases (6%).The malignant cases included endometrial carcinomas in 6(6%) cases. Post Menopausal bleeding was managed according to the current Guidelines. Thus Dilatation & curettage can be recommended in peripheral centers with limited facilities as it is an easy procedure, sophisticated equipment is not required and this gives chance to differentiate benign and malignant lesions in postmenopausal bleeding .
